These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 11495074)

  • 41. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
    van Pinxteren B; Numans ME; Bonis PA; Lau J
    Cochrane Database Syst Rev; 2000; (2):CD002095. PubMed ID: 10796857
    [TBL] [Abstract][Full Text] [Related]  

  • 42. On-demand PPI requirements in patients with endoscopy-negative GERD.
    Juul-Hansen P; Rydning A
    J Clin Gastroenterol; 2004 Oct; 38(9):746-9. PubMed ID: 15365398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Esomeprazole: a review of its use in the management of acid-related disorders.
    Scott LJ; Dunn CJ; Mallarkey G; Sharpe M
    Drugs; 2002; 62(10):1503-38. PubMed ID: 12093317
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the efficacy and safety of pantoprazole magnesium and pantoprazole sodium in the treatment of gastro-oesophageal reflux disease: a randomized, double-blind, controlled, multicentre trial.
    Hein J
    Clin Drug Investig; 2011; 31(9):655-64. PubMed ID: 21819161
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of 7-day therapy with different doses of the proton pump inhibitor lansoprazole on the intragastric pH in healthy human subjects.
    Harder H; Teyssen S; Stephan F; Pfützer R; Kiel G; Fuchs W; Singer MV
    Scand J Gastroenterol; 1999 Jun; 34(6):551-61. PubMed ID: 10440603
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of acute and chronic administration of the GABA B agonist baclofen on 24 hour pH metry and symptoms in control subjects and in patients with gastro-oesophageal reflux disease.
    Ciccaglione AF; Marzio L
    Gut; 2003 Apr; 52(4):464-70. PubMed ID: 12631652
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Treatment of patients with heartburn without endoscopic evaluation: on-demand treatment after effective continuous administration of lansoprazole 15 mg.
    Bigard MA; Genestin E
    Aliment Pharmacol Ther; 2005 Oct; 22(7):635-43. PubMed ID: 16181303
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effect of the GABA(B) agonist baclofen in patients with symptoms and duodeno-gastro-oesophageal reflux refractory to proton pump inhibitors.
    Koek GH; Sifrim D; Lerut T; Janssens J; Tack J
    Gut; 2003 Oct; 52(10):1397-402. PubMed ID: 12970129
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hiatal hernia is the key factor determining the lansoprazole dosage required for effective intra-oesophageal acid suppression.
    Frazzoni M; De Micheli E; Grisendi A; Savarino V
    Aliment Pharmacol Ther; 2002 May; 16(5):881-6. PubMed ID: 11966495
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.
    Katz PO; Koch FK; Ballard ED; Bagin RG; Gautille TC; Checani GC; Hogan DL; Pratha VS
    Aliment Pharmacol Ther; 2007 Jan; 25(2):197-205. PubMed ID: 17229243
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ; Nikolopoulou V; Kouklakis G; Paraskevas E; Avgerinos A; Tsianos E; Triantafillidis JK;
    Curr Med Res Opin; 2005 Apr; 21(4):603-10. PubMed ID: 15899110
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole.
    Graham DY; Agrawal NM; Campbell DR; Haber MM; Collis C; Lukasik NL; Huang B;
    Arch Intern Med; 2002 Jan; 162(2):169-75. PubMed ID: 11802750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of increasing esomeprazole and pantoprazole doses on acid control in patients with symptoms of gastro-oesophageal reflux disease: a randomized, dose-response study.
    Wilder-Smith C; Backlund A; Eckerwall G; Lind T; Fjellman M; Röhss K
    Clin Drug Investig; 2008; 28(6):333-43. PubMed ID: 18479175
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole.
    Baldi F; Cappiello R; Cavoli C; Ghersi S; Torresan F; Roda E
    World J Gastroenterol; 2006 Jan; 12(1):82-8. PubMed ID: 16440422
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The prophylactic use of a proton pump inhibitor before food and alcohol.
    O'Leary C; McCarthy J; Humphries M; Shanahan F; Quigley E
    Aliment Pharmacol Ther; 2003 Mar; 17(5):683-6. PubMed ID: 12641517
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of rabeprazole and omeprazole on the onset of gastro-oesophageal reflux disease symptom relief during the first seven days of treatment.
    Bytzer P; Morocutti A; Kennerly P; Ravic M; Miller N;
    Scand J Gastroenterol; 2006 Oct; 41(10):1132-40. PubMed ID: 16990197
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Therapeutic choices in reflux disease: defining the criteria for selecting a proton pump inhibitor.
    Freston JW
    Am J Med; 2004 Sep; 117 Suppl 5A():14S-22S. PubMed ID: 15478848
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Omeprazole. A review of its use in Helicobacter pylori infection, gastro-oesophageal reflux disease and peptic ulcers induced by nonsteroidal anti-inflammatory drugs.
    Langtry HD; Wilde MI
    Drugs; 1998 Sep; 56(3):447-86. PubMed ID: 9777317
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.